Literature DB >> 16847424

Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.

Sylke Schneider1, David J Park, Dongyun Yang, Anthony El-Khoueiry, Andy Sherrod, Susan Groshen, Oscar Streeter, Syma Iqbal, Kathleen D Danenberg, Heinz-Josef Lenz.   

Abstract

Recurrence is a significant clinical problem for patients with rectal cancer treated with adjuvant chemoradiation. Previous studies have suggested that determining intratumoral gene expression of key genes may be helpful in predicting clinical outcome of patients with gastrointestinal malignancies undergoing chemotherapy. The role of molecular predictors for prediction of recurrence in the setting of adjuvant chemoradiotherapy is not well established. The present study was designed to identify a genetic profile that would be associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation therapy. A retrospective study with a longitudinal cohort and a cross-sectional cohort of 67 patients with locally advanced rectal cancer who underwent cancer resection, followed by 5-fluorouracil (5-FU) plus pelvic radiation was conducted. Total RNA was extracted from formalin-fixed, paraffin-embedded, laser-captured-microdissected tissue. We determined mRNA levels of genes involved in the 5-FU pathway (thymidylate synthase, dihydropyrimidine dehydrogenase), DNA-repair (excision-repair cross-complementing factor 1, Rad51), angiogenesis/radiation sensitivity [vascular endothelial growth factor (VEGF)] and radio-sensitivity [epidermal growth factor receptor (EGFR)] in tumor tissue and tumor-adjacent normal tissue by quantitative reverse transcriptase-polymerase chain reaction. In univariate analysis, only intratumoral gene expression level of VEGF (P = 0.055) was associated with recurrence, whereas elevated mRNA expression levels of thymidylate synthase (P = 0.008), VEGF (P = 0.023) and EGFR (P = 0.004) in tumor-adjacent normal tissue were significantly associated with recurrence. Multivariate analysis using recursive partitioning indicated that distinct groups of recurrence could be defined by elevated mRNA expression levels of VEGF, EGFR in tumor-adjacent normal tissue, and Rad51 in tumor tissue. These data suggest that the genetic profile of the tumor-adjacent normal tissue may be associated with treatment failure, indicating that tumor microenvironment may be more important in the development of recurrence of rectal tumors than formerly expected.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16847424     DOI: 10.1097/01.fpc.0000220563.44724.6d

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  9 in total

1.  High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients.

Authors:  Lui Ng; Hung-Sing Li; Abraham Tak-Ka Man; Ariel Ka-Man Chow; Dominic Chi-Chung Foo; Oswens Siu-Hung Lo; Roberta Wen-Chi Pang; Wai-Lun Law
Journal:  Cells       Date:  2022-06-06       Impact factor: 7.666

2.  The importance of -460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer.

Authors:  Torben F Hansen; Karen-Lise G Spindler; Karen A Lorentzen; Dorte A Olsen; Rikke F Andersen; Jan Lindebjerg; Ivan Brandslund; Anders Jakobsen
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-11       Impact factor: 4.553

3.  Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.

Authors:  A Pohl; A El-Khoueiry; D Yang; W Zhang; G Lurje; Y Ning; T Winder; S Hu-Lieskoven; S Iqbal; K D Danenberg; M Kahn; J-L Teo; J Shriki; J Stebbing; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2012-01-10       Impact factor: 3.550

4.  Differences in miRNA expression in early stage lung adenocarcinomas that did and did not relapse.

Authors:  Mick D Edmonds; Christine M Eischen
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

5.  Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.

Authors:  Jinjin Shao; Zhifei Xu; Xueming Peng; Min Chen; Yuanrun Zhu; Li Xu; Hong Zhu; Bo Yang; Peihua Luo; Qiaojun He
Journal:  PLoS One       Date:  2016-01-11       Impact factor: 3.240

6.  Replication Study: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma.

Authors:  John Repass
Journal:  Elife       Date:  2018-03-13       Impact factor: 8.140

7.  Hierarchical investigating the predictive value of p53, COX2, EGFR, nm23 in the post-operative patients with colorectal carcinoma.

Authors:  Peng Du; Bin Xu; Dachuan Zhang; Yingjie Shao; Xiao Zheng; Xiaodong Li; Yuqi Xiong; Changping Wu; Jingting Jiang
Journal:  Oncotarget       Date:  2017-01-03

8.  AKAP3 correlates with triple negative status and disease free survival in breast cancer.

Authors:  Rezvan Esmaeili; Keivan Majidzadeh-A; Leila Farahmand; Maryam Ghasemi; Malihe Salehi; Ali Reza Khoshdel
Journal:  BMC Cancer       Date:  2015-10-12       Impact factor: 4.430

9.  HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.

Authors:  Hiroyuki Matsuda; Carole G Campion; Kyoko Fujiwara; Jin Ikeda; Suzanne Cossette; Thomas Verissimo; Maiko Ogasawara; Louis Gaboury; Kosuke Saito; Kenya Yamaguchi; Satoru Takahashi; Morito Endo; Noboru Fukuda; Masayoshi Soma; Pavel Hamet; Johanne Tremblay
Journal:  Oncotarget       Date:  2017-05-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.